Teva (NYSE: TEVA) files Form 144 for rollover/compensation share resales

Rhea-AI Filing Summary

Teva Pharmaceutical Industries submitted a Form 144 notice reporting proposed sales of ordinary shares tied to rollover/compensation transactions and prior dispositions. The filing lists multiple lot sizes dated 03/03/2026 and 03/04/2026, including quantities of 24,900, 33,512, and 23,251 shares. The excerpt also shows 153,251 shares sold during the past three months on 05/14/2026 for $5,457,368.64. The filing names Citigroup Global Markets as a broker and identifies the transactions as compensation ordinary shares or shares from rollover.

Insights

Securities Compliance Analyst

Form 144 documents proposed resale of Teva ordinary shares tied to rollover/compensation lots.

The filing lists multiple specific lots with dates 03/03/2026 and 03/04/2026 and quantities including 24,900, 33,512, and 23,251 shares. A separate entry shows 153,251 shares sold on 05/14/2026 for $5,457,368.64.

These notices are procedural disclosures required under Rule 144; cash‑flow treatment and whether proceeds are received by Teva or selling holders are not stated in the excerpt. Subsequent filings or broker disclosures would show actual sale execution and purchaser details.

Equity Capital Markets Specialist

Broker listed as Citigroup; transactions labeled as compensation/rollover lots.

The cover shows Citigroup Global Markets as the broker and multiple lots described as "SHARES FROM ROLLOVER" or "COMPENSATION ORDINARY SHARES." The excerpt attaches specific share counts to those lot descriptions.

Because this is a resale notice, the filing itself is administrative. Execution details, exact timing of brokerage placements, and whether Teva receives proceeds are not provided in the excerpt.

Key Figures

Lot - 03/03/2026: 24,900 shares Lot - 03/04/2026 (example): 33,512 shares Lot - 03/04/2025: 23,251 shares +3 more

6 metrics

Lot - 03/03/2026 24,900 shares SHARES FROM ROLLOVER, dated <date>03/03/2026</date>

Lot - 03/04/2026 (example) 33,512 shares SHARES FROM ROLLOVER, dated <date>03/04/2026</date>

Lot - 03/04/2025 23,251 shares SHARES FROM ROLLOVER, dated <date>03/04/2025</date>

Sold past 3 months 153,251 shares Disposition date <date>05/14/2026</date>

Proceeds reported for recent sale $5,457,368.64 Sale on <date>05/14/2026</date>

Filing date shown 06/11/2026 Cover indicates <date>06/11/2026</date>

Key Terms

SHARES FROM ROLLOVER, COMPENSATION ORDINARY SHARES, Form 144

3 terms

SHARES FROM ROLLOVER financial

"line item describing source of securities, e.g., "SHARES FROM ROLLOVER""

COMPENSATION ORDINARY SHARES financial

"descriptor attached to several lots, e.g., "COMPENSATION ORDINARY SHARES""

Form 144 regulatory

"header and form type indicator, e.g., "144: Filer Information""

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
ORDINARY SHARES	CITIGROUP GLOBAL MARKETS 390 GREENWICH ST NEW YORK NY 10013	106563	3633304.91	1164426972	06/11/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ORDINARY SHARES	03/03/2026	SHARES FROM ROLLOVER	TEVA PHARMACEUTICAL INDUSTRIES LIMITED			24900	06/11/2026	COMPENSATION
ORDINARY SHARES	03/03/2026	SHARES FROM ROLLOVER	TEVA PHARMACEUTICAL INDUSTRIES LIMITED			24900	06/11/2026	COMPENSATION
ORDINARY SHARES	03/04/2026	SHARES FROM ROLLOVER	TEVA PHARMACEUTICAL INDUSTRIES LIMITED			33512	06/11/2026	COMPENSATION
ORDINARY SHARES	03/04/2025	SHARES FROM ROLLOVER	TEVA PHARMACEUTICAL INDUSTRIES LIMITED			23251	06/11/2026	COMPENSATION

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Kalif Eliyahu Sharon TEVA PHARMACEUTICAL INDUSTRIES LIMITED 124 DVORA HANEVI'A ST. TEL AVIV L3 6944020	ORDINARY SHARES	05/14/2026	153251	5457368.64

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does TEVA's Form 144 list?

The Form 144 lists proposed resales of ordinary shares tied to rollover/compensation lots dated 03/03/2026 and 03/04/2026. It includes specific lot sizes such as 24,900, 33,512, and 23,251 shares.

How many TEVA shares were reported sold in the past three months?

The excerpt shows 153,251 shares sold during the past three months on 05/14/2026. The reported sale amount for that disposition is $5,457,368.64.

Who is the broker listed on TEVA's Form 144?

The broker identified in the excerpt is Citigroup Global Markets at 390 Greenwich St, New York, NY. The broker is named on the securities-to-be-sold section of the filing.

Are the reported lots described as compensation or rollover?

Yes. The filing labels several lots as "SHARES FROM ROLLOVER" and "COMPENSATION ORDINARY SHARES," associating the listed quantities with those descriptions on the dates shown.

Does the Form 144 state who receives sale proceeds?

The provided excerpt does not state proceeds recipients. The filing lists quantities and broker details but does not attach a cash‑flow treatment or indicate whether proceeds go to the issuer or selling holders.